AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03882567 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electro Neuro adaptative Regulator
Description: The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance
Study NCT04209166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Description: Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
Study NCT03530683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1.
Study NCT04328090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer based Antimicrobial stewardship (AMS) intervention system
Description: 1. Re-evaluation alerts and decision support for the duration of antimicrobial treatment.~2. Re-evaluation alerts and decision support for the choice of antimicrobial.~3. Quality control audit and feedback.
Study NCT04209166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs+Mood Stabilizer
Description: Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
Study NCT04050618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocufilcon D control lens
Description: hydrogel contact lens
Study NCT04050618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A control lens
Description: hydrogel contact lens
Study NCT00097448 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: prednisone
Description: Oral, 19 days
Study NCT00097448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone sodium succinate
Description: Four intratympanic injections delivered to the middle ear over 2 weeks
Study NCT02292693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy. Laryngoscopy with Miller blade
Study NCT04209166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs+Quetiapine
Description: Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
Study NCT04209166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual Treatment
Description: Patients' treatment will be decided by the clinical doctor.
Study NCT02466191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Study NCT02466191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study NCT00655226 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis C educational support groups
Description: Hepatitis C educational support groups
Study NCT00655226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy skills based group sessions
Description: Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
Study NCT02250157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oratecan
Study NCT02120456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204
Study NCT02120456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03199924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Intramuscular injection of 75mg / 3ml of Diclofenac solution
Study NCT03199924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
Study NCT03199924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
Study NCT03449277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Tablet
Description: oral labetalol tablets and oral nifedipine tablets
Study NCT02098707 — intervention group
Intervention type: OTHER
Intervention: Stabilometric Platform
Description: Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
Study NCT03583840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ScreenMen website
Description: An educational website that aims to improve evidence-based health screening uptake in men
Study NCT03205046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
Study NCT03205046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vistusertib
Description: Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
Study NCT04441437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-oriented training with a dynamic hand splint
Description: In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
Study NCT04441437 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Task-oriented training without a dynamic hand splint
Description: In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
Study NCT01459588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose Based Eye Drop Formulation A
Description: Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
Study NCT01459588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose Based Eye Drop Formulation B
Description: Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Study NCT01459588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
Description: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Study NCT00138801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Study NCT01459588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose Based Lubricant Eye Drops
Description: Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
Study NCT01362608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab, ACZ885
Description: Canakinumab and placebo matching to triamcinolone acetonide
Study NCT00138801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study NCT02292693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Direct laryngoscopy. Laryngoscopy with Macintosh blade
Study NCT01362608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Triamcinolone acetonide 40 mg and placebo matching to canakinumab
Study NCT02734745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flash glucose monitoring
Description: Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
Study NCT02292693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McCoy
Description: Direct laryngoscopy. Laryngoscopy with McCoy blade
Study NCT02152306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan and Amlodipine
Study NCT02152306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Study NCT03194126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mifepristone + Misoprostol OR oxytocine + laminaria
Description: Three laminaria placed 12 hours prior to administration of misoprostol
Study NCT03194126 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mifepristone + Misoprostol OR oxytocine
Description: standart support
Study NCT03777059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant tablet
Study NCT03777059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching atogepant tablets
Study NCT03777059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching atogepant tablets
Study NCT04915443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periotome
Description: Dental instrument used to perform atraumatic dental extraction.~After the initial de attachment, the periotome was inserted between the root and the bone parallel to the long axis of the root and pushed apically to the maximum depth that the tissue allowes severing the PDL and leaving it for 10-15 seconds allowing the biomechanical creep to occur.~This proses is repeated at different points of entries at all the different surfaces of the tooth.
Study NCT04915443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezotome
Description: Dental device used for many purposes one of which is performing atraumatic dental extraction.~An LC2 tip was used for all the procedures and it was inserted between the tooth root and the bone parallel to the long axis of the root and moved in a sweeping motion 3-4mm toward the apex severing the PDL.
Study NCT02403999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test shampoo
Description: Participants used Oilatum Soothe \& Protect Shampoo at home in place of their usual wash product at least twice weekly for a two week period.
Study NCT02403999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test bath foam
Description: Participants used Oilatum Soothe \& Protect Bath Foam at home in place of their usual wash product at least twice weekly for a two week period.
Study NCT02403999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test head to toe wash
Description: Participants used Oilatum Soothe \& Protect Head to Toe Wash at home in place of their usual wash product at least twice weekly for a two week period.
Study NCT01841723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02884089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally
Study NCT02884089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered orally
Study NCT02884089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Administered intravenously (IV)
Study NCT02884089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iohexol
Description: Administered intravenously (IV)
Study NCT02884089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06161792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8 mg RCN3028
Description: Oral
Study NCT06161792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT02866838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: intravenous
Study NCT02866838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: intravenous
Study NCT03217929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-taVNS
Description: Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
Study NCT03126266 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: re-irradiation
Description: if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
Study NCT00705172 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Prader-Willi syndrome children treated with at least one dose of Norditropin®
Study NCT01841723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy
Study NCT01841723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT02309541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: feedback canceller algorithm (Firmware)
Description: The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
Study NCT02309541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: feedback canceller algorithm (Firmware)
Description: The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
Study NCT02503696 — intervention group
Intervention type: DEVICE
Intervention: Stool Collection Kit
Description: Stool Collection Kit.
Study NCT03906929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: buried intramedullary K-wire
Description: Using of buried kirschner wire in pediatric forearm fixation
Study NCT03906929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exposed intramedullary K-wire
Description: Using of exposed kirschner wire in pediatric forearm fixation
Study NCT02780115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
Study NCT02780115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
Study NCT02735759 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Photoacoustic flow cytometry device
Description: The device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. Anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. Patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.
Study NCT01153815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1358820(Botulinum toxin type A)
Description: GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)
Study NCT01153815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04105673 — intervention group
Intervention type: OTHER
Intervention: Clinical examination and survey
Description: Children will be seen during an one consultation. A clinical examination and survey are realized.
Study NCT00711295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
Description: Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
Study NCT02780115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Vehicle
Description: Vehicle to AGN-199201
Study NCT02780115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 Vehicle
Description: Vehicle to AGN-190584
Study NCT01841723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT01841723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT01841723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound
Study NCT02029911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Endometrial Ablation System
Description: Ablation of the endometrial lining of the uterus using the Aurora System
Study NCT03891602 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)
Description: Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
Study NCT03891602 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Trust in the Medical
Description: Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84.
Study NCT03891602 — intervention group
Intervention type: BEHAVIORAL
Intervention: Decision Conflict Scale (DCS) - Lung Cancer Screening
Description: The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict.
Study NCT03891602 — intervention group
Intervention type: BEHAVIORAL
Intervention: Shared Decision Making Questionnaire (SDM-Q)- Patient
Description: Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94.
Study NCT03891602 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stage of Readiness for Smoking Cessation - Contemplation Ladder
Description: Among current smokers